Zacks Research Has Positive Estimate for STERIS Q2 Earnings

STERIS plc (NYSE:STE) – Research analysts at Zacks Research raised their Q2 2027 EPS estimates for shares of STERIS in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.58 for the quarter, up from their prior estimate of $2.51. The consensus estimate for STERIS’s current full-year earnings is $9.15 per share.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the prior year, the company posted $2.03 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the company. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Stephens restated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research note on Thursday, November 7th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Finally, JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Monday, November 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

STERIS Stock Down 0.1 %

Shares of STERIS stock opened at $218.87 on Monday. STERIS has a twelve month low of $195.50 and a twelve month high of $248.24. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $224.60 and its 200 day moving average is $228.15. The company has a market cap of $21.60 billion, a price-to-earnings ratio of 49.97 and a beta of 0.85.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS’s payout ratio is 52.05%.

Insider Buying and Selling at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 35.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On STERIS

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ashton Thomas Securities LLC bought a new position in shares of STERIS during the 3rd quarter valued at about $25,000. Central Pacific Bank Trust Division bought a new position in STERIS during the third quarter valued at approximately $28,000. Versant Capital Management Inc grew its holdings in STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 181 shares in the last quarter. Brown Brothers Harriman & Co. increased its stake in STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Finally, Isthmus Partners LLC purchased a new stake in shares of STERIS during the 2nd quarter worth approximately $44,000. Institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.